Patents

US 8021668 B2: Integrin alpha L I domain mutants with increased binding affinity

Granted
2011-09-20
Filed
2006-12-12 application 12097004
Type
Utility · 6 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present invention provides an isolated polypeptide capable of binding to aCAM-1, comprising the integrin (XL I domain or biologically active portion thereof, wherein one or more residues is substituted, wherein the substituted polypeptide binds ICAM-I at a higher affinity than wild type integrin CCL protein. The invention provides a method for inhibiting ICAM-I and a pharmaceutical composition comprising an integrin (XL I domain polypeptide or biologically active portion of the polypeptides. The invention also provides a method of treating or preventing an LFA-I mediated ICAM-1 associated disease such as inflammation, artherosclerosis, allograft rejection, diabetes, T-cell mediated sensitization reaction, psoriasis, HIV infection, or rheumatoid arthritis.

Source: PVGPATDIS, file of 2026-04-10 (ipg110920.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Immune Disease Institute 8 patentsUS company or organizationBoston, MAImmune Disease Institute Inc Nonprofit FUZZY medium confidence: same name (governing-board words and legal endings aside) and statePVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Moonsoo JinIthaca, NY8PVGPATDIS, file of 2026-04-10
Timothy A. SpringerSharon, MA10PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
C07KPeptidesC07K14/70546PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P3/10PVGPATDIS, file of 2026-04-10
A61KPreparations for medical, dental or toiletry purposesA61K38/00PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2008-06-20Assignment
Assignment of assignor's interest
SPRINGER, TIMOTHY signed 2008-05-10
JIN, MOONSOO signed 2008-05-19
IMMUNE DISEASE INSTITUTE, INC. BOSTON, MA21125/450ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.